SynerFuse

About:

SynerFuse is a provider of traditional spine implants intended to offer long-term pain management without the use of addictive opioids

Website: https://www.synerfuse.com

Description:

SynerFuse is a provider of traditional spine implants intended to offer long-term pain management without the use of addictive opioids. The company's technologies synergistically fuse with traditional spine implants to offer a more efficient and effective solution to long-term pain following back surgery, enabling physicians to improve spine implant outcomes with a drug-free pain management system. SynerFuse combines two FDA-approved technologies and synergistically fuses both in order to attack the problem of long-term post-surgery lower-back pain, with a preemptive, drug-free pain management system. It’s simple and brilliant. The company makes traditional spine implants more successful and cost-effective by embedding active neuromodulation therapy at the time surgeons are performing fusion back surgery. SynerFuse was founded in 2015 and is headquartered in Minneapolis, Minnesota, United States.

Total Funding Amount:

$7.07M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Minneapolis, Minnesota, United States

Founded Date:

2015-01-01

Contact Email:

info(AT)synerfuse.com

Founders:

Gregory F. Molnar, Justin Zenanko

Number of Employees:

1-10

Last Funding Date:

2021-04-20

IPO Status:

Private

Industries:

© 2025 bioDAO.ai